165 related articles for article (PubMed ID: 1793151)
1. Intra-arterial cisplatin given prior to surgery in osteosarcoma: grade of necrosis and size of tumor as major prognostic factors.
Quintana J; Beresi V; DelPozo H; Latorre JJ; Henriquez A; Chamas N; Diaz V; Geldres V; Sepulveda L; Macho L
Am J Pediatr Hematol Oncol; 1991; 13(3):269-73. PubMed ID: 1793151
[TBL] [Abstract][Full Text] [Related]
2. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
3. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
4. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.
Bacci G; Picci P; Ruggieri P; Mercuri M; Avella M; Capanna R; Brach Del Prever A; Mancini A; Gherlinzoni F; Padovani G
Cancer; 1990 Jun; 65(11):2539-53. PubMed ID: 2337871
[TBL] [Abstract][Full Text] [Related]
5. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
6. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
7. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
8. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
12. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
[TBL] [Abstract][Full Text] [Related]
13. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
17. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity.
Zhang HJ; Yang JJ; Lu JP; Lai CJ; Sheng J; Li YX; Hao Q; Zhang SM; Gupta S
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):672-8. PubMed ID: 19296158
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering.
Meyers PA; Heller G; Vlamis V
Cancer Treat Res; 1993; 62():309-22. PubMed ID: 7682091
[No Abstract] [Full Text] [Related]
19. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.
Bacci G; Picci P; Ferrari S; Casadei R; Brach Del Prever A; Tienghi A; Mancini A
J Chemother; 1993 Aug; 5(4):237-46. PubMed ID: 8229152
[TBL] [Abstract][Full Text] [Related]
20. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma.
Cassano WF; Graham-Pole J; Dickson N
Cancer; 1991 Nov; 68(9):1899-902. PubMed ID: 1913541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
